Marinomed Biotech AG had a role in study design, data collection and analysis, decision to publish, preparation of the manuscript and financing the processing charge of the manuscript. Marinomed Biotech AG ( provided support in form of salaries for all authors employed by Marinomed Biotech AG. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: All relevant data are within the manuscript and its Supporting Information files.įunding: This work was co-funded by the Austrian Science Promotion Agency (FFG) project number 880687 ( ). Received: AugAccepted: NovemPublished: February 17, 2021Ĭopyright: © 2021 Morokutti-Kurz et al. Polyak, University of Washington, UNITED STATES (2021) Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro. Accordingly, our in vitro data on SARS-CoV-2 spike pseudotyped lentivirus and replication competent SARS-CoV-2 suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections.Ĭitation: Morokutti-Kurz M, Fröba M, Graf P, Große M, Grassauer A, Auth J, et al. In vitro data on iota-carrageenan against various Rhino- and endemic Coronaviruses showed similar IC 50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction of severity and duration of symptoms of common cold caused by various respiratory viruses. Experiments with patient isolated wild type SARS-CoV-2 virus showed an inhibition of replication in a similar range. SARS-CoV-2 spike pseudotyped lentivirus particles were efficiently neutralized with an IC 50 value of 2.6 μg/ml iota-carrageenan. Here, we show that iota-carrageenan can inhibit the cell entry of the SARS-CoV-2 spike pseudotyped lentivirus in a dose dependent manner. Attachment and entry of coronaviruses including SARS-CoV-2 is mainly mediated by the spike glycoprotein. 229940113118 Carrageenan Drugs 0.In the absence of a vaccine and other effective prophylactic or therapeutic countermeasures the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) remains a significant public health threat.235000010418 carrageenan Nutrition 0.000 claims abstract description 185.239000000679 carrageenan Substances 0.000 claims abstract description 190.229920001525 carrageenan Polymers 0.000 claims abstract description 192.230000003449 preventive Effects 0.000 title abstract description 5.230000001225 therapeutic Effects 0.000 title abstract description 10.200000000015 coronavirus disease 2019 Diseases 0.000 title abstract description 22.
Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Active Application number US16/900,488 Inventor Julio César Vega Current Assignee (The listed assignees may be inaccurate.
#Iota carrageenan nasal spray pdf#
Google Patents Preventive and therapeutic treatment for COVID 19 and any other disease caused by SARS CoV 2ĭownload PDF Info Publication number US11013687B1 US11013687B1 US16/900,488 US202016900488A US11013687B1 US 11013687 B1 US11013687 B1 US 11013687B1 US 202016900488 A US202016900488 A US 202016900488A US 11013687 B1 US11013687 B1 US 11013687B1 Authority US United States Prior art keywords solution nasal xylitol iota carrageenan carrageenan Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google Patents US11013687B1 - Preventive and therapeutic treatment for COVID 19 and any other disease caused by SARS CoV 2 US11013687B1 - Preventive and therapeutic treatment for COVID 19 and any other disease caused by SARS CoV 2
0 kommentar(er)
